Tratamiento y áreas de incertidumbre | 13 JUL 17

Avances recientes en el tratamiento de la infección por Helicobacter pylori

El incremento de la resistencia a los antibióticos de Helicobacter pylori unido a la ausencia de una ATB alternativos, desafían nuestra capacidad para luchar de manera eficaz contra esta bacteria en el año 2017
Autor/a: Javier Molina-Infante,Rodolfo Corti, Judith Doweck y colaboradores Acta Gastroenterol Latinoam 2017;47: 75-85
INDICE:  1. Página 1 | 2.  Referencias bilibiográficas
Referencias bilibiográficas

1.    Fock KM, Graham DY, Malfertheiner P. Helicobacter pylori research: historical insights and future directions. Nat Rev Gastroenterol Hepatol 2013; 10: 495-500.
2.    Graham DY, Fischbach L. Helicobacter pylori treatment in the era of increasing antibiotic resistance. Gut 2010; 59: 1143-53.
3.    Thung I, Aramin H, Vavinskaya V, Gupta S, Park JY, Crowe SE, Valasek MA. Review article: the global emergence of Helicobacter pylori antibiotic resistance. Aliment Pharmacol Ther 2016; 43: 514-33.
4.    Malfertheiner P, Megraud F, O'Morain CA, Gisbert JP, Kuipers EJ, Axon AT, Bazzoli F, Gasbarrini A, Atherton J, Graham DY, Hunt R, Moayyedi P, Rokkas T, Rugge M, Selgrad M, Suerbaum S, Sugano K, El-Omar EM; European Helicobacter and Microbiota Study Group and Consensus panel. Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report. Gut 2017: 66: 6-30.
5.    Gisbert JP, Molina-Infante J, Amador J, Bermejo F, Bujanda L, Calvet X, Castro-Fernández M, Cuadrado-Lavín A, Elizalde JI, Gene E, Gomollón F, Lanas Á, Martín de Argila C, Mearin F, Montoro M, Pérez-Aisa Á, Pérez-Trallero E, McNicholl AG. IV Spanish Consensus Conference on Helicobacter pylori infection treatment. Gastroenterol Hepatol 2016; 39: 697-721.
6.    Fallone CA, Chiba N, van Zanten SV, Fischbach L, Gisbert JP, Hunt RH, Jones NL, Render C, Leontiadis GI, Moayyedi P, Marshall JK. The Toronto Consensus for the Treatment of Helicobacter pylori Infection in Adults. Gastroenterology 2016; 151: 51-69. 
7.    Graham DY, Laine L. The Toronto Helicobacter pylori Consensus in Context. Gastroenterology 2016; 151: 9-12.
8.    Gisbert JP. Is culture necessary before first-line treatment for Helicobacter pylori infection?.  Intern Med 2011; 50: 2717.
9.    Klotz U, Schwab M, Treiber G. CYP2C19 polymorphism and proton pump inhibitors. Basic Clin Pharmacol Toxicol 2004; 95: 2-8.
10.    McNicholl AG, Linares PM, Nyssen OP, Calvet X, Gisbert JP. Meta-analysis: esomeprazole or rabeprazole vs. first-generation pump inhibitors in the treatment of Helicobacter pylori infection. Aliment Pharmacol Ther 2012; 36: 414-425.
11.    Tang HL, Li Y, Hu YF, Xie HG, Zhai SD. Effects of CYP2C19 loss-of-function variants on the eradication of H. pylori infection in patients treated with proton pump inhibitor-based triple therapy regimens: a meta-analysis of randomized clinical trials. PLoS One 2013; 8: e62162.
12.     Kagami T, Sahara S, Ichikawa H, Uotani T, Yamade M, Sugimoto M, Hamaya Y, Iwaizumi M, Osawa S, Sugimoto K, Miyajima H, Furuta T. Potent acid inhibition by vonoprazan in comparison with esomeprazole, with reference to CYP2C19 genotype. Aliment Pharmacol Ther 2016; 43: 1048-1059.
13.    Murakami K, Sakurai Y, Shiino M, Funao N, Nishimura A, Asaka M. Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomised, double-blind study. Gut 2016; 65: 1439-1446. 
14.    Matsumoto H, Shiotani A, Katsumata R, Fujita M, Nakato R, Murao T, Ishii M, Kamada T, Haruma K, Graham DY. Helicobacter pylori Eradication with Proton Pump Inhibitors or Potassium-Competitive Acid Blockers: The Effect of Clarithromycin Resistance. Dig Dis Sci 2016; 61: 3215-3220.
15.    Megraud F, Coenen S, Versporten A, Kist M, Lopez-Brea M, Hirschl AM, Andersen LP, Goossens H, Glupczynski Y. Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption. Gut 2013; 62: 34-42.
16.    Nishizawa T, Maekawa T, Watanabe N, Harada N, Hosoda Y, Yoshinaga M, Yoshio T, Ohta H, Inoue S, Toyokawa T, Yamashita H, Saito H, Kuwai T, Katayama S, Masuda E, Miyabayashi H, Kimura T, Nishizawa Y, Takahashi M, Suzuki H. Clarithromycin Versus Metronidazole as First-line Helicobacter pylori Eradication: A Multicenter, Prospective, Randomized Controlled Study in Japan. J Clin Gastroenterol 2015;49: 468-471.
17.    Yuan Y, Ford AC, Khan KJ, Gisbert JP, Forman D, Leontiadis GI, Tse F, Calvet X, Fallone C, Fischbach L, Oderda G, Bazzoli F, Moayyedi P. Optimum duration of regimens for Helicobacter pylori eradication. Cochrane Database Syst Rev 2013; 12: CD008337.
18.    Molina-Infante J, Gisbert JP. Optimizing clarithromycin-containing therapy for Helicobacter pylori in the era of antibiotic resistance. World J Gastroenterol 2014; 20: 10338-100347. 
19.    Graham DY, Lee YC, Wu MS. Rational Helicobacter pylori therapy: evidence-based medicine rather than medicine-based evidence. Clin Gastroenterol Hepatol 2014; 12: 177-186. 
20.    Molina-Infante J, Shiotani A. Practical Aspects in Choosing a Helicobacter pylori Therapy. Gastroenterol Clin North Am 2015; 44: 519-535.
21.    Molina-Infante J, Lucendo AJ, Angueira T, Rodriguez-Tellez M, Perez-Aisa A, Balboa A, Barrio J, Martin-Noguerol E, Gomez-Rodriguez BJ, Botargues-Bote JM, Gómez-Camarero J, Huerta A, Modolell I, Ariño I, Herranz-Bachiller MT, Bermejo F, McNicholl AG, O'Morain C, Gisbert JP; European Registry on H. pylori management (Hp‐EuReg). Optimised empiric triple and concomitant therapy for Helicobacter pylori eradication in clinical practice: the OPTRICON study. Aliment Pharmacol Ther 2015; 41: 581-589.
22.    Nyssen OP, McNicholl AG, Megraud F, Savarino V, Oderda G, Fallone CA, Fischbach L, Bazzoli F, Gisbert JP. Sequential versus standard triple first-line therapy for Helicobacter pylori eradication. Cochrane Database Syst Rev 2016; 6: CD009034.
23.    McNicholl AG, Gisbert JP. Non-bismuth quadruple concomitant treatment: systematic review and meta-analysis. Am J Gastroenterol 2016; en prensa.
24.    McNicholl AG, Molina-Infante J, Bermejo F, Harb Y, Ferrer-Barcelo L, Modolell I, Anton R, Perez-Aısa A, Alcedo J, Barenys M, Fernandez-Bermejo M,  Algaba A, Fernandez-Moreno N, Barrio J, Gomez J, Pozzati L, Ortun J, Rodrigo L, Canelles P, Huguet-Malavés JM, Huerta-Madrigal A, Tomas A, Vega AB, Andreu V,  Herranz M, Almela P, Cosme A, Marin AC, Gisbert JP. Non bismuth quadruple "concomitant" therapies in the eradication of Helicobacter pylori: standard vs. optimized (14 days, high-dose PPI) regimens in clinical practice. United European Gastroenterol Journal 2015; 3: A65.
25.    Graham DY, Lew GM, Klein PD, Evans DG, Evans DJ Jr, Saeed ZA, Malaty HM. Effect of treatment of Helicobacter pylori infection on the long-term recurrence of gastric or duodenal ulcer. A randomized, controlled study. Ann Intern Med 1992; 116: 705-708.
26.    Borody TJ, Andrews P, Fracchia G, Brandl S, Shortis NP, Bae H. Omeprazole enhances efficacy of triple therapy in eradicating Helicobacter pylori. Gut 1995; 37: 477-481.
27.    Gene E, Calvet X, Azagra R, Gisbert JP. Triple vs. quadruple therapy for treating Helicobacter pylori infection: A metaanalysis. Aliment Pharmacol Ther 2003; 17: 1137-1143.
28.    Luther J, Higgins PD, Schoenfeld PS, Moayyedi P, Vakil N, Chey WD. Empiric quadruple vs. triple therapy for primary treatment of Helicobacter pylori infection: Systematic review and meta-analysis of efficacy and tolerability. Am J Gastroenterol 2010; 105: 65-73.
29.    Venerito M, Krieger T, Ecker T, Leandro G, Malfertheiner P. Meta-analysis of bismuth quadruple therapy versus clarithromycin triple therapy for empiric primary treatment of Helicobacter pylori infection. Digestion 2013; 88: 33-45.
30.    O'Morain C, Borody T, Farley A, De Boer WA, Dallaire C, Schuman R, Piotrowski J, Fallone CA, Tytgat G, Mégraud F, Spénard J; International multicentre study. Efficacy and safety of single-triple capsules of bismuth biskalcitrate, etronidazole and tetracycline, given with omeprazole, for the eradication of Helicobacter pylori: an international multicentre study. Aliment Pharmacol Ther 2003; 17: 415-420.
31.    Laine L, Hunt R, El-Zimaity H, Nguyen B, Osato M, Spénard J. Bismuth-based quadruple therapy using a single capsule of bismuth biskalcitrate, metronidazole, and tetracycline given with omeprazole versus omeprazole, amoxicillin, and clarithromycin for eradication of Helicobacter pylori in duodenal ulcer patients: a prospective, randomized, multicenter, North American trial.  Am J Gastroenterol 2003; 98: 562-567.
32.    Malfertheiner P, Bazzoli F, Delchier JC, Celiñski K, Giguère M, Rivière M, Mégraud F; Pylera Study Group. Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomised, open-label, non-inferiority, phase 3 trial.  Lancet 2011; 377: 905-913.
33.    McNicholl AG, Megraud F, Tepes B, Venerito M, Przytulski K, Delchier JC; Courillon-Mallet A, Molard R, Vaira D, A. Perez-Aisa A, Fernandez-Salazar L, Bujanda L, Ortuño J, Donday MG, Nyssen OP, O’ Morain C, Gisbert JP. Hp-EuReg investigators. Pan-European Registry on Helicobacter pylori Management (Hp- EuReg): Interim analysis of the single-capsule bismuth quadruple treatment (Pylera ®). United European Gastroenterol J 2016; Suppl A-111.
34.    Liou JM, Fang YJ, Chen CC, Bair MJ, Chang CY, Lee YC, Chen MJ, Chen CC, Tseng CH, Hsu YC, Lee JY, Yang TH, Luo JC, Chang CC, Chen CY, Chen PY, Shun CT, Hsu WF, Hu WH, Chen YN, Sheu BS, Lin JT, Wu JY, El-Omar EM, Wu MS; Taiwan Gastrointestinal Disease and Helicobacter Consortium. Concomitant, bismuth quadruple, and 14-day triple therapy in the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial. Lancet 2016; 388: 2355-2365.
35.    Dore MP, Lu H, Graham DY. Role of bismuth in improving Helicobacter pylori eradication with triple therapy. Gut 2016; 65: 870-8. 
36.    Zhang W, Chen Q, Liang X, Liu W, Xiao S, Graham DY, Lu H. Bismuth, lansoprazole, amoxicillin and metronidazole or clarithromycin as first-line Helicobacter pylori therapy. Gut 2015; 64: 1715-1720.
37.    Kekilli M, Onal IK, Ocal S, Dogan Z, Tanoglu A. Inefficacy of triple therapy and comparison of two different bismuth-containing quadruple regimens as a firstline treatment option for helicobacter pylori. Saudi J Gastroenterol 2016; 22: 366-369. 
38.    McNicholl, A Lucendo, I Modolell, J Molina-Infante, Á Pérez-Aisa, C de la Coba, L Bujanda, M Castro-Fernandez, J Barrio, J Perez-Lasala, JL Domínguez-Jiménez, Ó Núñez, J Alcedo, PL González-Cordero, J Hinojosa, P Varela, HA Galán, MG Donday, OP Nyssen, M Caldas, F Megraud, C O’Morain, JP Gisbert. Addition of bismuth to standard triple to optimize eradication therapy in Spain: A prospective multicenter analysis of the European Registry on H. pylori Management; en prensa.
39.    Molina-Infante J, Gisbert JP. Update on the efficacy of triple therapy for Helicobacter pylori infection and clarithromycin resistance rates in Spain (2007-2012). Gastroenterol Hepatol 2013; 36: 375-381. 
40.    Marin AC, McNicholl AG, Gisbert JP. A review of rescue regimens after clarithromycin-containing triple therapy failure (for Helicobacter pylori eradication). Expert Opin Pharmacother 2013; 14: 843-861.
41.    Gisbert JP, Perez-Aisa A, Bermejo F, Castro-Fernandez M, Almela P, Barrio J, et al. Second-line therapy with levofloxacin after failure of treatment to eradicate Helicobacter pylori infection: Time trends in a Spanish multicenter study of 1000 patients. J Clin Gastroenterol 2013; 47: 130-135.
42.    Cuadrado-Lavin A, Salcines-Caviedes JR, Carrascosa MF, Mellado P, Monteagudo I, Llorca J, et al. Antimicrobial susceptibility of Helicobacter pylori to six antibiotics currently used in Spain. J Antimicrob Chemother 2012; 67: 170-173.
43.    Navarro-Jarabo JM, Fernández-Sánchez F, Fernández-Moreno N, Hervas-Molina AJ, Casado-Caballero F, Puente-Gutierrez JJ, Pallares-Manrique H, Rodríguez-Ramos C, Fernández-Gutierrez C, Pérez-Aisa A, Rivas-Ruiz F, Montiel Quezel-Guerraz N. Prevalence of Primary Resistance of Helicobacter pylori to Clarithromycin and Levofloxacin in Southern Spain. Digestion 2015; 92: 78-82.
44.    Liao J, Zheng Q, Liang X, Zhang W, Sun Q, Liu W, Xiao S, Graham DY, Lu H. Effect of fluoroquinolone resistance on 14-day levofloxacin triple and triple plus bismuth quadruple therapy. Helicobacter 2013; 18: 373-377.
45.    Gisbert JP, Romano M, Molina-Infante J, Lucendo AJ, Medina E, Modolell I, Rodríguez-Tellez M, Gomez B, Barrio J, Perona M, Ortuño J, Ariño I, Domínguez-Muñoz JE, Perez-Aisa Á, Bermejo F, Domínguez JL, Almela P, Gomez-Camarero J, Millastre J, Martin-Noguerol E, Gravina AG, Martorano M, Miranda A, Federico A, Fernandez-Bermejo M, Angueira T, Ferrer-Barcelo L, Fernández N, Marín AC, McNicholl AG. Two-week, high-dose proton pump inhibitor, moxifloxacin triple Helicobacter pylori therapy after failure of standard triple or non-bismuth quadruple treatments. Dig Liver Dis 2015; 47: 108-113.
46.    Gisbert JP, Romano M, Gravina AG, Solís-Muñoz P, Bermejo F, Molina-Infante J, Castro-Fernández M, Ortuño J, Lucendo AJ, Herranz M, Modolell I, Del Castillo F, Gómez J, Barrio J, Velayos B, Gómez B, Domínguez JL, Miranda A, Martorano M, Algaba A, Pabón M, Angueira T, Fernández-Salazar L, Federico A, Marín AC, McNicholl AG. Helicobacter pylori second-line rescue therapy with levofloxacin- and bismuth-containing quadruple therapy, after failure of standard triple or non-bismuth quadruple treatments. Aliment Pharmacol Ther 2015; 41: 768-775. 
47.    Delchier JC, Malfertheiner P, Thieroff-Ekerdt R. Use of a combination formulation of bismuth, metronidazole and tetracycline with omeprazole as a rescue therapy for eradication of Helicobacter pylori. Aliment Pharmacol Ther 2014; 40: 171-177. 
48.    Muller N, Amiot A, Le Thuaut A, Bastuji-Garin S, Deforges L, Delchier JC. Rescue therapy with bismuth-containing quadruple therapy in patients infected with metronidazole-resistant Helicobacter pylori strains. Clin Res Hepatol Gastroenterol 2016; 40: 517-524.
49.    Liang X, Xu X, Zheng Q, Zhang W, Sun Q, Liu W, Xiao S, Lu H. Efficacy of bismuth-containing quadruple therapies for clarithromycin-, metronidazole-, and fluoroquinolone-resistant Helicobacter pylori infections in a prospective study. Clin Gastroenterol Hepatol 2013; 1: 802-807.
50.    Chen Q, Zhang W, Fu Q, Liang X, Liu W, Xiao S, Lu H. Rescue Therapy for Helicobacter pylori Eradication: A Randomized Non-Inferiority Trial of Amoxicillin or Tetracycline in Bismuth Quadruple Therapy. Am J Gastroenterol 2016; 111: 1736-1742.
51.    Gisbert JP, Calvet X. Review article: Rifabutin in the treatment of refractory Helicobacter pylori infection. Aliment Pharmacol Ther 2012; 35: 209-221.
52.    Gisbert JP, Castro-Fernandez M, Perez-Aisa A, Cosme A, Molina-Infante J, Rodrigo L, Modolell I, Cabriada JL, Gisbert JL, Lamas E, Marcos E, Calvet X. Fourth-line rescue therapy with rifabutin in patients with three Helicobacter pylori eradication failures. Aliment Pharmacol Ther 2012; 35: 941-947. 
53.    Borody TJ, Pang G, Wettstein AR, Clancy R, Herdman K, Surace R, Llorente R, Ng C.  Efficacy and safety of rifabutin-containing 'rescue therapy' for resistant Helicobacter pylori infection. Aliment Pharmacol Ther 2006; 23: 481-488.
54.    Mori H, Suzuki H, Matsuzaki J, Tsugawa H, Fukuhara S, Miyoshi S, Hirata K, Seino T, Matsushita M, Nishizawa T, Masaoka T, Kanai T. Rifabutin-based 10-day and 14-day triple therapy as a third-line and fourth-line regimen for Helicobacter pylori eradication: A pilot study. United European Gastroenterol J 2016; 4: 380-387. 
55.    Ciccaglione AF, Tavani R, Grossi L, Cellini L, Manzoli L, Marzio L. Rifabutin Containing Triple Therapy and Rifabutin with Bismuth Containing Quadruple Therapy for Third-Line Treatment of Helicobacter pylori Infection: Two Pilot Studies. Helicobacter 2016; 21: 375-381.
56.    Corti RE, Bori J, Améndola R. Helicobacter pylori. Terapias de erradicación y rescate. En Tópicos destacados en patología gastroduodenal. Ed Content Medicine, Bs As 2013.
57.    Zerbetto De Palma G, Mendiondo N,  Wonaga A, Viola L, Ibarra D, Campitelli E, Salim N, Corti R, Goldman C, Catalano M. Ocurrence of mutations in the antimicrobial target genes related to levofloxacin, claritromycin and amoxicillin resistence in H pylori isolates from Buenos Aires city. Microb Drug Resist 2016; 8: 256-272.
58.    Zerbetto G, Mendiondo N, Salim R, Améndola R, Doweck J, Argonz J, Zerbo O, Catalano M, Corti RE. Polimorfismos genómicos de la enzima hepática citocromo P4502C19 y del gen que codifica las P glicoproteínas predominantes en nuestra población. Acta Gastroenterol Latinoam 2014; S 10: GO-013.
59.    Zerbetto G, Mendiondo N, Améndola R, Salim N, Argonz J, Zerbo O, Catalano M, Corti RE. Erradicación del Helicobacter Pylori. ¿Necesidad en terapéutica individualizadas?. Acta Gatroenterol Latinoam 2014; S 81: GP-210.
60.    Corti RE. Helicobacter pylori. Epidemiología, Diagnóstico, Tratamiento. Ed Cilsa, Bs As 2001.
61.     Stollman N. Helicobacter pylori infection in the era of antibiotic resistence. Gastroenterol Hepatol 2016; 2: 122-125.

 

Comentarios

Para ver los comentarios de sus colegas o para expresar su opinión debe ingresar con su cuenta de IntraMed.

AAIP RNBD
Términos y condiciones de uso | Política de privacidad | Todos los derechos reservados | Copyright 1997-2024